Novartis to buy out kidney specialist Chinook Therapeutics in $3.5B deal

No­var­tis is putting down $3.2 bil­lion in cash to ac­quire kid­ney-fo­cused biotech Chi­nook Ther­a­peu­tics and its two late-stage drugs for a rare chron­ic kid­ney dis­ease. The Swiss phar­ma gi­ant al­ready has a top drug, ip­ta­co­pan, that it said showed promise in IgA nephropa­thy, which…#novartis #kidney #vasnarasimhan #atrasentan #unlock
Source: Reuters: Health - Category: Consumer Health News Source Type: news